AstraZeneca PLC (AZN) Earnings History
Elite Compounder36 years of earnings data (1990–2025) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality
Loading earnings history...
AstraZeneca PLC (AZN) Earnings Overview
As of September 23, 2026, AstraZeneca PLC (AZN) reported trailing twelve-month net income of $10.45B, reflecting +45.3% year-over-year growth. The company earned $6.70 per diluted share over the past four quarters, with a net profit margin of 17.5%.
Looking at the long-term picture, AZN's 5-year EPS compound annual growth rate (CAGR) stands at +21.8%, indicating exceptional earnings growth. The company achieved its highest annual net income of $10.26B in fiscal 2025, representing a new all-time high.
AstraZeneca PLC maintains industry-leading profitability with a gross margin of 81.9%, operating margin of 23.4%, and net margin of 17.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including PFE ($4.33B net income, 12.4% margin), MRK ($3.17B net income, 28.1% margin), LLY ($26.71B net income, 31.7% margin), AZN has outperformed on profitability metrics. Compare AZN vs PFE →
AZN Earnings vs Peers
Earnings metrics vs comparable public companies
AZN Historical Earnings Data (1990–2025)
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $10.26B | +45.8% | $13.74B | $13.08 | 17.5% | 23.4% |
| 2024 | $7.04B | +18.1% | $10.00B | $9.00 | 13.0% | 18.5% |
| 2023 | $5.96B | +81.1% | $8.19B | $7.62 | 13.0% | 17.9% |
| 2022 | $3.29B | +2835.7% | $3.76B | $4.22 | 7.4% | 8.5% |
| 2021 | $112M | -96.5% | $1.06B | $0.16 | 0.3% | 2.8% |
| 2020 | $3.20B | +139.4% | $5.16B | $4.88 | 12.0% | 19.4% |
| 2019 | $1.33B | -38.1% | $2.92B | $2.06 | 5.5% | 12.0% |
| 2018 | $2.15B | -28.2% | $3.39B | $3.40 | 9.8% | 15.3% |
| 2017 | $3.00B | -14.2% | $3.68B | $4.74 | 13.4% | 16.4% |
| 2016 | $3.50B | +23.9% | $4.90B | $5.52 | 15.2% | 21.3% |
| 2015 | $2.83B | +129.1% | $4.11B | $4.46 | 11.4% | 16.7% |
| 2014 | $1.23B | -51.8% | $2.14B | $1.96 | 4.6% | 8.0% |
| 2013 | $2.56B | -59.0% | $3.71B | $4.08 | 9.9% | 14.4% |
| 2012 | $6.24B | -37.1% | $8.15B | $9.86 | 22.3% | 29.1% |
| 2011 | $9.92B | +23.1% | $12.79B | $14.60 | 29.5% | 38.1% |
| 2010 | $8.05B | +7.1% | $11.49B | $11.14 | 24.2% | 34.5% |
| 2009 | $7.52B | +23.3% | $11.54B | $10.38 | 22.9% | 35.2% |
| 2008 | $6.10B | +9.0% | $9.14B | $8.40 | 19.3% | 28.9% |
| 2007 | $5.59B | -7.4% | $8.09B | $7.46 | 18.9% | 27.4% |
| 2006 | $6.04B | +28.4% | $8.22B | $7.70 | 22.8% | 31.0% |
| 2005 | $4.71B | +28.4% | $6.50B | $5.82 | 19.6% | 27.1% |
| 2004 | $3.66B | +20.7% | $4.55B | $436.00 | 17.1% | 21.2% |
| 2003 | $3.04B | +7.0% | $4.01B | $356.00 | 16.1% | 21.3% |
| 2002 | $2.84B | -31.7% | $4.01B | $3.28 | 15.9% | 22.5% |
| 2001 | $4.16B | +63.6% | $4.16B | $3.30 | 25.2% | 25.2% |
| 2000 | $2.54B | +122.4% | $3.67B | $2.86 | 14.0% | 20.2% |
| 1999 | $1.14B | -3.6% | $3.43B | $1.28 | 7.5% | 22.7% |
| 1998 | $1.19B | -1.8% | $2.43B | $2.92 | 10.5% | 21.4% |
| 1997 | $1.21B | +9.6% | $1.79B | $2.54 | 14.1% | 20.9% |
| 1996 | $1.10B | +112.1% | $1.79B | $2.32 | 12.0% | 19.4% |
| 1995 | $519M | -25.0% | $1.28B | $1.10 | 6.9% | 16.9% |
| 1994 | $693M | +8.6% | $1.03B | $1.46 | 9.9% | 14.7% |
| 1993 | $638M | +425.4% | $1.04B | $1.50 | 9.7% | 15.9% |
| 1992 | $121M | -81.2% | $429M | $0.34 | 2.0% | 7.1% |
| 1991 | $646M | +50.8% | $1.28B | $1.80 | 8.8% | 17.4% |
| 1990 | $428M | - | $1.16B | $1.20 | 5.8% | 15.7% |
Download Data
Export AZN earnings history in CSV or JSON format
Free sign-in required to download data
AZN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
36+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AZN — Frequently Asked Questions
Quick answers to the most common questions about buying AZN stock.
What is AZN earnings per share (EPS)?
AZN trailing twelve-month (TTM) diluted EPS is $6.70, reflecting +45.3% year-over-year growth. The 5-year EPS CAGR is +21.8%. Complete EPS history from 1990 to 2025 is available in the table on this page.
What is AstraZeneca PLC's net income?
AstraZeneca PLC (AZN) trailing twelve-month net income is $10.4B as of 2025. Earnings grew +45.3% year-over-year. AstraZeneca PLC has been profitable for 36 consecutive years.
Is AZN profitable?
Yes, AZN is profitable with a TTM net income of $10.4B and a net profit margin of +17.5%. AstraZeneca PLC has generated profits for 36 consecutive years.
What is AZN's earnings growth rate?
AZN compound annual EPS growth rates (CAGR): 1-Year: +45.3%, 3-Year: +45.8%, 5-Year: +21.8%, 10-Year: +11.4%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1990 to 2025.
What are AZN's profit margins?
AstraZeneca PLC net profit margin is +17.5%, operating margin is +23.4%, and gross margin is +81.9%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +22.9%.
Is AZN growing earnings?
Yes, AZN earnings are accelerating — EPS growth of +45.3% exceeds the 5-year CAGR of +21.8%. TTM net income reached $10.4B. Earnings momentum is strengthening.
What was AZN's best earnings year?
AstraZeneca PLC's highest annual net income on record is $10.3B, achieved in fiscal year 2025. Earnings history on this page spans 1990 to 2025 and includes all annual and quarterly figures.
What were AZN's earnings last quarter?
AZN's most recent reported quarter was Q2 2026. Net income was $2.5B with diluted EPS of $1.59. For a full breakdown of all quarters, see the quarterly earnings table on this page.